23 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of novel BCL6-Targeting PROTACs with effective antitumor activities against DLBCL in vitro and in vivo.
East China Normal University
Facilitating the development of molecular glues: Opportunities from serendipity and rational design.
Sichuan University
Improved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6
The Institute of Cancer Research
B-cell Lymphoma 6 Inhibitors: Current Advances and Prospects of Drug Development for Diffuse Large B-cell Lymphomas.
East China Normal University
Optimizing Shape Complementarity Enables the Discovery of Potent Tricyclic BCL6 Inhibitors.
The Institute of Cancer Research
Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface.
Dana-Farber Cancer Institute
Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of
East China Normal University and Shanghai Fengxian District Central Hospital Joint Center For Translational Medicine
Free Ligand 1D NMR Conformational Signatures To Enhance Structure Based Drug Design of a Mcl-1 Inhibitor (AZD5991) and Other Synthetic Macrocycles.
Astrazeneca
Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.
University of Maryland
A genetically selected cyclic peptide inhibitor of BCL6 homodimerization.
University of Southampton
Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design.
University of Maryland
Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-Driven Fragment-Based Approach.
Takeda Pharmaceutical
Discovery of a novel B-cell lymphoma 6 (BCL6)-corepressor interaction inhibitor by utilizing structure-based drug design.
Takeda Pharmaceutical
X-ray Structures of Target-Ligand Complexes Containing Compounds with Assay Interference Potential.
Rheinische Friedrich-Wilhelms-Universit£T
Discovery of Pyrazolo[1,5-a]pyrimidine B-Cell Lymphoma 6 (BCL6) Binders and Optimization to High Affinity Macrocyclic Inhibitors.
Astrazeneca
AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES
Vesper Bio
Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders
Rugen Holdings (Cayman)